Couteau C, Armand J P
Service d'oncologie médicale, hôpital Tenon, Paris, France.
Bull Cancer. 1998 Dec;Spec No:47-50.
Irinotecan is a new topoisomerase I inhibitor. It has demonstrated antitumor activity in solid tumors, independently of the histologic type, and in squamous cervical carcinoma. Its original mechanism of action offers the possibility to combine it with other drugs. In vitro and in vivo studies have demonstrated synergistic activity between irinotecan, cisplatin and etoposide. This article reviews the main published phases I and II studies with irinotecan. The limiting toxicity of combination schedules in neutropenia. The best results were obtained with the association cisplatin-irinotecan in lung cancer. For the combination etoposide-irinotecan the best schedule of administration remains to be determined.
伊立替康是一种新型拓扑异构酶I抑制剂。它已在实体瘤中显示出抗肿瘤活性，与组织学类型无关，在宫颈鳞癌中也有活性。其最初的作用机制为它与其他药物联合使用提供了可能性。体外和体内研究已证明伊立替康、顺铂和依托泊苷之间具有协同活性。本文综述了已发表的关于伊立替康的主要I期和II期研究。联合用药方案的剂量限制性毒性为中性粒细胞减少。顺铂-伊立替康联合方案在肺癌中取得了最佳结果。对于依托泊苷-伊立替康联合方案，最佳给药方案仍有待确定。
